VIBERZI 75 MG
VIBERZI · DIN 02460890 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is VIBERZI?
VIBERZI 75 MG contains VIBERZI. It is listed in the Health Canada Drug Product Database under DIN 02460890, held by ABBVIE CORPORATION. Health Canada currently lists it as marketed, status dated 09-Jun-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VIBERZI used for?
Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02460890 |
|---|---|
| Brand name | VIBERZI |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 75 MG |
| Schedule | PRESCRIPTION |
| Health Canada status | MARKETED |
| Status date | 09-Jun-2025 |
How is it administered?
Recommended dose is 100 mg orally twice daily with food. Starting dose of 75 mg BID for patients unable to tolerate 100 mg or for patients 65 years and older.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), typically 15-30°C for tablets.
How is it supplied?
Bottles of 60 tablets.
Contraindications
Hypersensitivity; biliary duct obstruction; sphincter of Oddi disease; patients without a gallbladder; alcoholism (>3 drinks/day); history of pancreatitis; hepatic impairment; severe constipation.
Warnings and precautions
Serious risk of pancreatitis and sphincter of Oddi spasm, especially in patients without a gallbladder. Risk of severe constipation and psychological dependence.
Is VIBERZI in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by ABBVIE CORPORATION, last seen 09 Mar 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.